Soonmo Peter Kang

17.8k total citations · 1 hit paper
64 papers, 2.9k citations indexed

About

Soonmo Peter Kang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Soonmo Peter Kang has authored 64 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Soonmo Peter Kang's work include Cancer Immunotherapy and Biomarkers (37 papers), Esophageal Cancer Research and Treatment (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Soonmo Peter Kang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (37 papers), Esophageal Cancer Research and Treatment (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Soonmo Peter Kang collaborates with scholars based in United States, France and Japan. Soonmo Peter Kang's co-authors include Scot Ebbinghaus, Anthony M. Joshua, Muhammad Wasif Saif, Adil Daud, Mark J. Ratain, Antoni Ribas, Marcus O. Butler, Leila Khoja, Caroline Robert and Jared Lunceford and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Soonmo Peter Kang

62 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

2018 362 citations Manish A. Shah, Takashi Kojima et al. profile →

Peers

Soonmo Peter Kang

ONCOL

PRM

IMMUN

SURGE

Simon Pernot France

Steven J. Lemery United States

Archie Tse United States

Kun He United States

Syma Iqbal United States

Hendrik‐Tobias Arkenau United Kingdom

Adnan Nagrial Australia

Austin G. Duffy United States

Renuka Iyer United States

Osama E. Rahma United States

Simon Pernot France

Soonmo Peter Kang

2.2k ×1.0

ONCOL

1.1k ×1.3

PRM

938 ×1.4

IMMUN

547 ×0.9

SURGE

759 ×1.3

Citations per year, relative to Soonmo Peter Kang Soonmo Peter Kang (= 1×) peers Simon Pernot

Countries citing papers authored by Soonmo Peter Kang

Since Specialization

Citations

This map shows the geographic impact of Soonmo Peter Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soonmo Peter Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soonmo Peter Kang more than expected).

Fields of papers citing papers by Soonmo Peter Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soonmo Peter Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soonmo Peter Kang. The network helps show where Soonmo Peter Kang may publish in the future.

Co-authorship network of co-authors of Soonmo Peter Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Soonmo Peter Kang. A scholar is included among the top collaborators of Soonmo Peter Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soonmo Peter Kang. Soonmo Peter Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Metges, Jean‐Philippe, Éric François, Manish A. Shah, et al.. (2019). The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Annals of Oncology. 30. iv130–iv130. 24 indexed citations

Tabernero, Josep, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2019). Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Annals of Oncology. 30. iv152–iv153. 16 indexed citations

Chung, Hyun Cheol, Yung‐Jue Bang, Charles S. Fuchs, et al.. (2019). KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Annals of Oncology. 30. iv25–iv25. 4 indexed citations

Shah, Manish A., Antoine Adenis, Peter C. Enzinger, et al.. (2019). Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. Journal of Clinical Oncology. 37(15_suppl). 4010–4010. 38 indexed citations

Wang, Meihua, Cong Chen, Thomas Jemielita, et al.. (2019). Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?. Journal for ImmunoTherapy of Cancer. 7(1). 39–39. 16 indexed citations

Díaz, Luis A., Dung T. Le, Takayuki Yoshino, et al.. (2018). KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology. 36(4_suppl). TPS877–TPS877. 34 indexed citations

Díaz, Luis A., Aurélien Marabelle, T.W. Kim, et al.. (2017). Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Annals of Oncology. 28. v128–v129. 52 indexed citations

Schadendorf, Dirk, Reinhard Dummer, Axel Hauschild, et al.. (2016). Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer. 67. 46–54. 64 indexed citations

Le, Dung T., Jennifer N. Uram, Hao Wang, et al.. (2016). Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). 103–103. 85 indexed citations

10.

Sachs, Jeffrey R., et al.. (2015). Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. Clinical Cancer Research. 22(6). 1318–1324. 112 indexed citations

11.

Khoja, Leila, Marcus O. Butler, Soonmo Peter Kang, Scot Ebbinghaus, & Anthony M. Joshua. (2015). Pembrolizumab. Journal for ImmunoTherapy of Cancer. 3(1). 36–36. 173 indexed citations

12.

Robert, Caroline, Anthony M. Joshua, Richard Kefford, et al.. (2015). Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. Journal of Clinical Oncology. 33(15_suppl). 9050–9050. 12 indexed citations

13.

Maitland, Michael L., Kailiang Wu, Yuyan Jin, et al.. (2012). Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling. Clinical Pharmacology & Therapeutics. 93(4). 345–351. 11 indexed citations

14.

Sharma, Manish, Soonmo Peter Kang, Theodore Karrison, et al.. (2012). Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients.. Journal of Clinical Oncology. 30(15_suppl). e13106–e13106. 3 indexed citations

15.

Kang, Soonmo Peter, Jacqueline Ramı́rez, Larry House, et al.. (2010). A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenetics and Genomics. 20(10). 638–641. 36 indexed citations

16.

Speed, William C., Soonmo Peter Kang, David Tuck, Lyndsay N. Harris, & Kenneth K. Kídd. (2009). Global variation in CYP2C8–CYP2C9 functional haplotypes. The Pharmacogenomics Journal. 9(4). 283–290. 46 indexed citations

17.

Kang, Soonmo Peter, Maritza Martel, & Lyndsay N. Harris. (2008). Triple negative breast cancer: current understanding of biology and treatment options. Current Opinion in Obstetrics & Gynecology. 20(1). 40–46. 56 indexed citations

18.

Kang, Soonmo Peter, et al.. (2008). Pseudocirrhosis in a pancreatic cancer patient with liver metastases: A case report of complete resolution of pseudocirrhosis with an early recognition and management. World Journal of Gastroenterology. 14(10). 1622–1622. 36 indexed citations

19.

You, Fanglei, Lisa Roberts, Soonmo Peter Kang, et al.. (2008). Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. Journal of Hematology & Oncology. 1(1). 2–2. 28 indexed citations

20.

Saif, Muhammad Wasif, Soonmo Peter Kang, & Edward Chu. (2006). Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies.. PubMed. 20(14 Suppl 10). 11–9. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact